Загрузка видео...

Не удалось загрузить видео

На главную

Carmelo is a top five SF ever if we going by eye test, stats, longevity, basketball evolution and ability 🤷🏽‍♂️ Skilled bully!

86,586 просмотров • 2 лет назад •via X (Twitter)

Комментарии: 10

Фото профиля Spence
Spence2 лет назад

Your eye test isn’t good. Basketball evolution? 🙄

Фото профиля Washed Gamer
Washed Gamer2 лет назад

“Melo is a top 5 SF ever if we just ignore facts” This is why Jamal Crawford is the best offensive shooting guard of all time

Фото профиля Legends of the Paul
Legends of the Paul2 лет назад

🤣🤣🤣 The worst opinions on this app Bron, Bird, Baylor, Durant, Dr. J, Pippen, Hondo, Kawhi, Barry are all undeniably better Then there’s guys like Pierce, King, English, Worthy, Wilkins, Butler who are easily in the convo for equal or better. Another 🗑️ take

Фото профиля 💎M͜͡i͜͡t͜͡o͜͡M͜͡a͜͡g͜͡i͜͡c💎
💎M͜͡i͜͡t͜͡o͜͡M͜͡a͜͡g͜͡i͜͡c💎2 лет назад

😂 if by eye test you mean watching a couple highlights of his middie pull-ups in each game and acting like that’s representative of the whole game

Фото профиля POLO ASSASSINS OUT NOW
POLO ASSASSINS OUT NOW2 лет назад

Of course he is…is this an argument?

Фото профиля Dime Dropper
Dime Dropper2 лет назад

🤣🤣🤣🤣

Фото профиля Basketball Visionaries
Basketball Visionaries2 лет назад

LeBron Bird Durant Dr.J Baylor Barry Havlicek Pippen Kawhi I’d argue that Carmelo is fighting Dominique for 10th

Фото профиля Andrew D
Andrew D2 лет назад

I’m a lifelong Knicks and Syracuse fan and can confidently say this is a 🤡 take. He’s not even a top 5 knick of all time, so he sure af isn’t a top 5 SF in nba history. Not close.

Фото профиля Ricky Chu
Ricky Chu2 лет назад

Def not top 5 SF

Фото профиля Tripp
Tripp2 лет назад

“Nothing but net every time” Right. EVERY TIME. Hilarious takes.

Похожие видео

Today’s guest on the Free Radicals podcast is Michael Ringel, JD PhD, COO Life Biosciences and former Managing Director at Boston Consulting Group. Michael is a leader in longevity and pharma who spent 25+ years advising top pharma companies on their R&D strategy. He is now COO at Life Biosciences where he is bringing the first ever partial epigenetic reprogramming therapy to human clinical trials - a major milestone for the longevity industry. In this episode, we discuss Michael’s insightful paper on why aging is an optimization by evolution, why that means it’s malleable, and how to push the longevity field forward. Michael also sits on the US board of Hevolution Foundation and on the board of the AFAR. Be sure to follow me and Eric Dai to stay up to date on the latest news in longevity biotech! 0:00 Intro 2:30 Why aging is an optimization by evolution 15:10 Why scientists miss the role of evolution in aging 19:31 Evidence that aging is a regulated process 24:40 Hormesis and adaptive stress responses 28:55 The promise of partial epigenetic reprogramming in humans 35:08 Life Bio's first therapy proceeding to clinical trials 47:47 Why targeting the eye, particularly glaucoma and NION, is a strategic choice 52:03 The pharma industry's perspective on anti-aging research 56:39 The importance of public engagement for funding and policy change 1:05:42 Reasons for optimism in longevity 1:08:26 Advice on how to have an impactful and interdisciplinary career 1:11:54 The ethical case for longevity 1:17:34 Concrete steps for audience members to support longevity research

Daniel Shur

16,988 просмотров • 5 месяцев назад